Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) has received an average rating of “Buy” from the nine ratings firms that are currently covering the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.50.
MNTA has been the topic of a number of recent research reports. Cowen and Company reaffirmed a “hold” rating on shares of Momenta Pharmaceuticals in a research note on Sunday, August 7th. Brean Capital set a $19.00 price target on Momenta Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 5th. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Tuesday, October 4th. Maxim Group downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating and set a $6.00 price target for the company. in a report on Wednesday, September 7th. Finally, Barclays PLC upgraded Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $13.00 to $19.00 in a report on Tuesday, October 11th.
In related news, President Craig A. Wheeler sold 5,880 shares of the stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $12.02, for a total value of $70,677.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 6.10% of the company’s stock.
A number of hedge funds have recently made changes to their positions in MNTA. Pacad Investment Ltd. bought a new stake in shares of Momenta Pharmaceuticals during the second quarter valued at about $103,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Momenta Pharmaceuticals during the second quarter valued at about $109,000. Jane Street Group LLC bought a new stake in shares of Momenta Pharmaceuticals during the second quarter valued at about $109,000. Mason Street Advisors LLC bought a new stake in shares of Momenta Pharmaceuticals during the second quarter valued at about $134,000. Finally, BlackRock Inc. increased its stake in shares of Momenta Pharmaceuticals by 220.1% in the second quarter. BlackRock Inc. now owns 13,446 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 9,245 shares in the last quarter. Hedge funds and other institutional investors own 81.09% of the company’s stock.
Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 11.38 on Tuesday. Momenta Pharmaceuticals has a 52-week low of $7.86 and a 52-week high of $18.85. The stock has a 50 day moving average price of $11.84 and a 200 day moving average price of $11.24. The stock’s market cap is $780.63 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.01. Momenta Pharmaceuticals had a negative return on equity of 28.76% and a negative net margin of 126.37%. The firm had revenue of $26.40 million for the quarter, compared to analyst estimates of $23.55 million. During the same quarter in the prior year, the company earned ($0.04) EPS. Momenta Pharmaceuticals’s revenue was down 41.2% on a year-over-year basis. On average, equities research analysts forecast that Momenta Pharmaceuticals will post ($1.25) EPS for the current year.